599P R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)

Carrasco, Javier;Beniuga, Gabriela;Mourin, Anne;Baldin, Paméla;Van den Eynde, Marc;et.al.
(2023) ESMO Congress 2023 — Location: (Spain) Madrid (20.October.2023)

Files

2023_Carrasco_ESMO_599P.pdf
  • Open Access
  • Adobe PDF
  • 89.9 KB
Download

Details

Authors
Show more
Abstract
BACKGROUND : There is a strong rationale to combine radiotherapy with immune checkpoint inhibitors (ICIs). This study evaluates this combination before surgery in locally advanced rectal cancer (LARC). [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Carrasco, J., Beniuga, G., Mourin, A., Baldin, P., Sinapi, I., Schroeder, D., De Cuyper, A., Sclafani, F., Hendlisz, A., van Laethem, J.-L., Boulanger, A.-S., Van Ooteghem, G., Dermine, A., Delmarcelle, S., Huyghe, N., Bar, I., & Van den Eynde, M. (2023). 599P R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC). Published. ESMO Congress 2023, (Spain) Madrid. https://doi.org/10.1016/j.annonc.2023.09.1790